Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Egorin

Showing results (61-70 of 159) with videos related to

Pageof 16
Sort By:
Cancer Research|November 1, 1979
Cellular accumulation and disposition of aclacinomycin AM J Egorin, R E Clawson, L A Ross, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusionN S Tchekmedyian, M J Egorin, B E Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1991
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamoleD L Trump, M J Egorin, A Forrest, et al.
Cancer Research|April 1, 1988
Metabolism of hexamethylene bisacetamide and its metabolites in leukemic cellsM J Egorin, S W Snyder, A S Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Development and validation of a pharmacokinetically based fixed dosing scheme for suraminL M Reyno, M J Egorin, M A Eisenberger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1984
The disposition of the new anthracycline antibiotic, menogarol, in miceP Dodion, B K Chang, M J Egorin, et al.
Cancer|January 1, 1989
A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusionJ J Lokich, M J Egorin, B E Cohen, et al.
Life Sciences|January 1, 1988
Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA)B A Conley, P S Callery, M J Egorin, et al.
Cancer Research|January 15, 1987
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusionM J Egorin, L M Sigman, D A Van Echo, et al.
Journal of Neurosurgery|May 1, 1984
The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppiesM J Egorin, E H Bellis, M Salcman, et al.
Pageof 16

Showing results (61-70 of 159) with videos related to

Sort By:
Pageof 16
Cancer Research|November 1, 1979
Cellular accumulation and disposition of aclacinomycin AM J Egorin, R E Clawson, L A Ross, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusionN S Tchekmedyian, M J Egorin, B E Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1991
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamoleD L Trump, M J Egorin, A Forrest, et al.
Cancer Research|April 1, 1988
Metabolism of hexamethylene bisacetamide and its metabolites in leukemic cellsM J Egorin, S W Snyder, A S Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Development and validation of a pharmacokinetically based fixed dosing scheme for suraminL M Reyno, M J Egorin, M A Eisenberger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1984
The disposition of the new anthracycline antibiotic, menogarol, in miceP Dodion, B K Chang, M J Egorin, et al.
Cancer|January 1, 1989
A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusionJ J Lokich, M J Egorin, B E Cohen, et al.
Life Sciences|January 1, 1988
Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA)B A Conley, P S Callery, M J Egorin, et al.
Cancer Research|January 15, 1987
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusionM J Egorin, L M Sigman, D A Van Echo, et al.
Journal of Neurosurgery|May 1, 1984
The pharmacology of diaziquone given in intravenous or intracarotid infusion to normal and intracranial tumor-bearing puppiesM J Egorin, E H Bellis, M Salcman, et al.
Pageof 16